Limosilactobacillus fermentum CECT5716, a probiotic strain isolated from human milk, has
reported beneficial effects on different gastrointestinal disorders. Moreover, it has shown its ability to
restore altered immune responses, in association with microbiome modulation in different pathological
conditions. Therefore, our aim was to assess the effects of a Limosilacbacillus fermentum CECT5716
in a rat experimental model of irritable bowel syndrome (IBS) that resembles human IBS. The experimental
IBS was induced by deoxycholic acid (DCA) in rats and then, Limosilactobacillus fermentum
CECT5716 (109 CFU/day/rat) was administered. Behavioral studies, hyperalgesia and intestinal
hypersensitivity determinations were performed and the impact of the probiotic on the inflammatory
and intestinal barrier integrity was evaluated. Additionally, the gut microbiota composition was
analyzed. Limosilactobacillus fermentum CECT5716 attenuated the anxiety-like behavior as well as the
visceral hypersensitivity and referred pain. Moreover, this probiotic ameliorated the gut inflammatory
status, re-establishing the altered intestinal permeability, reducing the mast cell degranulation and
re-establishing the gut dysbiosis in experimental IBS. Therefore, our results suggest a potential use of
Limosilactobacillus fermentum CECT5716 in clinical practice for the management of IBS patients.Junta de Andalucia A-CTS-447-UGR18
CTS 164Instituto de Salud Carlos IIIEuropean Commission PI19/01058
PI20/0144